NUZ — Neurizon Therapeutics Cashflow Statement
0.000.00%
- AU$56.62m
- AU$46.50m
Annual cashflow statement for Neurizon Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Changes in Working Capital | 0.951 | 1.53 | 1.13 | 1.08 | 0.867 |
Other Operating Cash Flow | |||||
Cash from Operating Activities | -1.27 | -0.938 | -1.33 | -1.56 | -5.17 |
Capital Expenditures | -0.03 | -0.102 | -0.043 | -0.035 | 0 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | -0.036 | 0 | -0 | -1.17 |
Acquisition of Business | |||||
Change in Net Intangibles | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.03 | -0.138 | -0.043 | -0.035 | -1.17 |
Financing Cash Flow Items | — | — | — | — | 0.035 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 2.09 | 1.22 | 0.771 | 1.89 | 13.3 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.79 | 0.14 | -0.605 | 0.29 | 7.01 |